---
title: "Is Alnylam Pharmaceuticals (ALNY) Undervalued On Strong New AMVUTTRA Data?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305576549.md"
description: "Alnylam Pharmaceuticals (ALNY) faces mixed signals: new five-year AMVUTTRA data shows durable reductions in mortality and cardiovascular events, yet the stock has fallen over 58% year-to-date. Analysts on Simply Wall St suggest ALNY is undervalued, citing a fair value of $299.96 against its current price of $165.04, driven by a deep RNAi pipeline. However, bears highlight execution risks and reliance on the TTR franchise despite strong clinical outcomes."
datetime: "2026-11-15T15:36:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305576549.md)
  - [en](https://longbridge.com/en/news/305576549.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305576549.md)
generator: "portal-rs"
---

# Is Alnylam Pharmaceuticals (ALNY) Undervalued On Strong New AMVUTTRA Data?

Alnylam Pharmaceuticals (ALNY) has become a focus for many investors after new five-year AMVUTTRA data presented at the American Heart Association Scientific Sessions showed significant, durable reductions in mortality and recurrent cardiovascular events in ATTR-CM.

Despite the strong AMVUTTRA data, Alnylam Pharmaceuticals’ recent trading tells a more cautious story. The 1-day share price return of 5.36% and 7-day gain of 5.84% come after a sharp 30-day share price decline of 28.81% and a year-to-date share price fall of 58.76%. The 1-year total shareholder return is down 63.26%, while the 3-year total shareholder return is slightly positive, suggesting short-term pressure but a mixed longer-term record.

Scan beyond Alnylam Pharmaceuticals and compare it with 36 healthcare AI stocks that are also working at the intersection of advanced therapeutics and data driven medicine.

Bulls point to AMVUTTRA’s five year outcomes and a deep RNAi pipeline. Bears focus on sharp share price declines and execution risk. Which case does Alnylam Pharmaceuticals’ current valuation lean toward as the numbers are unpacked next?

## Most Popular Narrative: 45% Undervalued

Alnylam Pharmaceuticals closed at $165.04, while the analyst consensus Narrative on Simply Wall St anchors fair value around $299.96. This points to a sizeable valuation gap that the narrative tries to explain through long term earnings and cash flow assumptions.

*The broad RNAi portfolio at Alnylam Pharmaceuticals, with more than 25 programs across rare, specialty and prevalent conditions and multiple pivotal studies underway, creates repeated opportunities for new approvals that could add incremental revenue streams and help spread fixed R&D and SG&A over a larger sales base, which may support earnings.*

See why 31 investors see Alnylam Pharmaceuticals as 45% undervalued.

**Result: Fair Value of $299.96 (UNDERVALUED)**

Still, the Alnylam Pharmaceuticals story carries real pressure points, including heavy reliance on the TTR franchise and uncertainty around AMVUTTRA access after recent guidance cuts.

Find out about the key risks to this Alnylam Pharmaceuticals narrative.

## Next Steps

Mixed signals around Alnylam Pharmaceuticals can make the story feel messy, which is exactly why you should study the data and form your own take. To pressure test that view against both the upside arguments and the red flags investors are watching, start with the 4 key rewards and 2 important warning signs.

## Looking for more investment ideas beyond Alnylam Pharmaceuticals?

If Alnylam Pharmaceuticals has sharpened your focus, do not stop there. Broader research now can give you more options when the next opportunity appears.

-   Target resilient balance sheets that can better handle shocks by scanning the list of solid balance sheet and fundamentals (24 results).
-   Hunt for quality companies that trade below their assessed worth by checking the 34 high quality undervalued stocks.
-   Spot lesser known businesses with strong fundamentals before the crowd notices by reviewing the 19 high quality undiscovered gems.

### Related Stocks

- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)

## Related News & Research

- [Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM | ALNY Stock News](https://longbridge.com/en/news/304881250.md)
- [Alnylam's Amvuttra shows sustained benefit in five-year ATTR-CM study data](https://longbridge.com/en/news/304880409.md)
- [We Believe Alnylam Pharmaceuticals' (NASDAQ:ALNY) Earnings Are A Poor Guide For Its Profitability](https://longbridge.com/en/news/304736195.md)
- [Alnylam Partner Regeneron's CIDEBsiRNA Cuts Liver Fat by Up to 80% in Early Trial](https://longbridge.com/en/news/305034308.md)
- [Alnylam Pharmaceuticals Shares Update About Phase 3 Nucresiran Study, Reaffirms FY26 Outlook](https://longbridge.com/en/news/303599634.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**